Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 3/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | RORB | Q92753 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986164 | 0.92 | AOC3 (0.35) | AOC3 | |
| SCHEMBL4864969 | 0.90 | SCD (0.42) | SCDAOC3MAPTPOLBRAB9A | |
| SCHEMBL4990577 | 0.90 | SCD (0.38) | SCDAOC3MAPTPOLBRAB9A | |
| SCHEMBL4877581 | 0.88 | AOC3 (0.36) | SCDAOC3MAPTPOLBRAB9A | |
| SCHEMBL4985430 | 0.88 | AOC3 (0.39) | AOC3MAPTPOLBRAB9ARXFP1 | |
| SCHEMBL4875659 | 0.88 | AOC3 (0.37) | AOC3POLB | |
| SCHEMBL4987280 | 0.87 | AOC3 (0.37) | AOC3 | |
| SCHEMBL4875750 | 0.87 | GHSR (0.36) | AOC3EPHX2 | |
| SCHEMBL4982248 | 0.87 | AOC3 (0.34) | AOC3MAPTPOLBRAB9A | |
| SCHEMBL4871391 | 0.86 | AOC3 (0.39) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | SCD 2681/4885AOC3 782/4885CSNK1D 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.